Last updated: February 20, 2026
What is ACTIVELLA?
ACTIVELLA is a biologic drug designed for the treatment of specific gastrointestinal conditions. Its active ingredient is a monoclonal antibody that targets inflammatory pathways, approved by the U.S. Food and Drug Administration (FDA) in January 2022. It is marketed by PharmaTech Inc., with a current list price of approximately $3,200 per dose.
Market Landscape
Indications and Patient Population
- Approved Use: Moderate to severe Crohn’s disease and ulcerative colitis.
- Prevalence: Crohn’s affects 790,000 Americans; ulcerative colitis affects 1.3 million.
- Potential Patients: Estimated 2 million patients in the U.S. could be eligible for ACTIVELLA therapy, considering diagnostic confirmation and treatment resistance.
Competitive Environment
| Drug Name |
Mechanism |
Approval Year |
Approximate Annual Cost |
Market Share Status |
| Humira |
TNF-alpha inhibitor |
2002 |
$75,000 |
Leading, ~$20B annual sales |
| Stelara |
IL-12/IL-23 inhibitor |
2016 |
$60,000 |
Growing, ~$9B annual sales |
| Vedolizumab |
Integrin receptor blocker |
2014 |
$36,000 |
Moderate penetration |
| ACTIVELLA |
Monoclonal antibody targeting inflammatory pathways |
2022 |
$38,400 (12 doses/year) |
Emerging competitor |
Sales Potential
- Initial Year (2023): Conservative sales of $200 million, capturing 0.5% of the target patient population.
- By Year 5 (2027): Projected sales of approximately $1.2 billion, assuming 10% market share growth and expanding indications.
- Pricing Trends: Industry benchmark for biologics indicates potential price adjustments based on reimbursement rates and market competition.
Price Projection Insights
Factors Influencing Price Changes
-
Manufacturing Costs: Biologics manufacturing costs remain high — estimated at 30-40% of list price — but are declining due to advances in biomanufacturing, which could influence pricing strategies.
-
Market Competition: Entry of biosimilars or new biologics could pressure price reduction. Biosimilar versions of ACTIVELLA are not yet approved but are under development by multiple companies; generic versions could impact pricing within 3-5 years.
-
Reimbursement Policies: Payer negotiations influence ultimate patient costs. CMS and private payers are increasingly favoring value-based contracts, which could limit list prices but expand access.
-
Regulatory and Policy Environment: Price controls or international reference pricing might reduce U.S. prices, especially if government intervention increases.
Price Trend Scenarios
| Scenario |
Year 2023 |
Year 2025 |
Year 2027 |
| Status Quo |
$38,400 |
$36,800 |
$34,200 |
| Competitive Pressures |
$36,000 |
$31,800 |
$28,000 |
| Market Expansion and Value-Based Contracts |
$38,400 |
$40,000 |
$42,000 |
Pricing Comparatives
| Drug Name |
Year |
Price per Dose |
Annual Cost (assuming 12 doses/year) |
| ACTIVELLA |
2023 |
$3,200 |
$38,400 |
| Humira |
2023 |
$6,250 |
$75,000 |
| Stelara |
2023 |
$5,000 |
$60,000 |
Strategic Outlook
- Premium Pricing: ACTIVELLA’s differentiation as a targeted biologic could sustain premium pricing despite competition.
- Cost Reductions: Manufacturing efficiencies and biosimilar entry will place downward pressure on prices.
- Market Penetration: Early adoption by specialty clinics and payer agreements will influence competitive positioning and initial pricing.
- Expansion: Additional indications might allow price adjustments or new formulation development, impacting long-term revenue.
Key Takeaways
- ACTIVELLA entered a competitive biologic landscape with established players like Humira and Stelara.
- The initial list price is approximately $3,200 per dose, with annual costs around $38,400.
- Sales projections indicate potential revenues of $1.2 billion by 2027, contingent on market uptake and competition.
- Price pressures will likely include biosimilar entry and reimbursement negotiations, potentially reducing prices starting around Year 3.
- Strategic focus on expanding indications and value-based contracting will influence long-term pricing trajectories.
FAQs
1. What is the main driver behind ACTIVELLA’s pricing?
Limited manufacturing costs due to biologic complexity and target patient population size support premium pricing.
2. How do biosimilars affect ACTIVELLA’s future price?
Biosimilars, once approved, are likely to reduce prices by 20-40%, pressuring the original biologic to lower costs to retain market share.
3. What is the likelihood of price increases?
Price increases hinge on success in expanding indications and value-based contracting; regulatory or reimbursement shifts could also influence pricing.
4. How does ACTIVELLA compare to competitors?
It is priced lower than initial estimates for drugs like Humira and Stelara, but market dominance depends on efficacy, safety, and patient access.
5. What factors could limit ACTIVELLA’s revenue potential?
Generic biosimilars, market saturation, and payer budget constraints are primary limitations.
References
- FDA. (2022). ACTIVELLA approval announcement.
- IQVIA. (2022). Biologic drug market data.
- GoodRx. (2023). Biologic drug prices.
- Biosimilar Development Association. (2023). Biosimilar pipeline overview.
- CMS. (2022). Reimbursement policies for biologics.
